CLINICAL TRIALS PROFILE FOR ENOXAPARIN SODIUM

All Clinical Trials for Enoxaparin Sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00077753 ↗	EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization	Completed	Sanofi	Phase 4	2002-02-01	Primary objective: - To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd Secondary objectives: - To assess the reduction in mortality rate at the end of the double-blind treatment period, at 3 (90 ± 10 days) and at 6 (180 ± 10 days) months from the time of entry to the study, in patients on extended prophylaxis - To assess the incidence of VTE at 3 months (90 ± 10 days) from the time of randomization to the study - To evaluate the safety of extended enoxaparin VTE prophylaxis in acutely ill medical patients with prolonged immobilization. Safety evaluation includes: - Major and minor hemorrhage - Heparin induced thrombocytopenia - Serious adverse events - To assess differences in levels of health-care utilization and cost between patients receiving extended VTE prophylaxis versus those receiving placebo.
NCT00077805 ↗	PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)	Completed	Sanofi	Phase 4	2003-08-01	Primary objective: - To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke. Secondary objectives: - To compare the incidence of VTE between the 2 treatment groups at 30, 60, and 90 days from the time of randomization - To compare neurologic outcomes between the 2 treatment groups, including incidence of stroke recurrence, rate of stroke progression, and patient functional status, during the 10 ± 4 days of treatment, and after 30, 60, and 90 days from the time of randomization - To evaluate the safety of using enoxaparin compared to UFH for VTE prevention in patients following acute ischemic stroke
NCT00077818 ↗	Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)	Completed	Sanofi	Phase 4	2002-06-01	The purpose of this study is to determine the efficacy and safety of enoxaparin compared to unfractionated heparin (UFH) for patients diagnosed with Acute Coronary Syndrome (ACS) in the emergency department (ED). Efficacy is assessed by using a composite score consisting of 30-day all-cause mortality, non-fatal myocardial infarction (MI) and recurrent angina requiring revascularization.
NCT00077844 ↗	Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)	Completed	Sanofi	Phase 2/Phase 3	2004-01-01	The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.
NCT00191724 ↗	Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study	Completed	Eli Lilly and Company	Phase 2	2004-09-01	An exploratory, multicenter, randomized, placebo-controlled, double blind, dose escalation study comparing a standard therapy for submassive pulmonary embolism (Enoxaparin sodium) to a combined therapy of Drotrecogin alfa (activated) plus Enoxaparin sodium.

Clinical Trial Conditions for Enoxaparin Sodium

Condition Name

Condition Name for Enoxaparin Sodium
Intervention	Trials
Venous Thromboembolism	16
Deep Vein Thrombosis	3
Myocardial Infarction	2
Atrial Fibrillation	2

Condition MeSH

Condition MeSH for Enoxaparin Sodium
Intervention	Trials
Thromboembolism	21
Venous Thromboembolism	19
Venous Thrombosis	6
Thrombosis	6

Clinical Trial Locations for Enoxaparin Sodium

Trials by Country

Trials by Country for Enoxaparin Sodium
Location	Trials
United States	28
Canada	10
Russian Federation	9
Italy	8
Poland	8

Trials by US State

Trials by US State for Enoxaparin Sodium
Location	Trials
New Jersey	7
Ohio	3
Pennsylvania	2
California	2
District of Columbia	1

Clinical Trial Progress for Enoxaparin Sodium

Clinical Trial Phase

Clinical Trial Phase for Enoxaparin Sodium
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for Enoxaparin Sodium
Clinical Trial Phase	Trials
Completed	36
Recruiting	6
Terminated	4

Clinical Trial Sponsors for Enoxaparin Sodium

Sponsor Name

Sponsor Name for Enoxaparin Sodium
Sponsor	Trials
Sanofi	16
Daiichi Sankyo Co., Ltd.	4
IWK Health Centre	1

Sponsor Type

Sponsor Type for Enoxaparin Sodium
Sponsor	Trials
Other	36
Industry	32

Clinical Trials Update, Market Analysis, and Projection for Enoxaparin Sodium

Last updated: January 27, 2026

Summary

Enoxaparin sodium, marketed under the brand name Lovenox, is a low-molecular-weight heparin (LMWH) used primarily for thromboprophylaxis and treating deep vein thrombosis (DVT), pulmonary embolism (PE), and other thrombotic conditions. This report presents an updated overview of clinical trials, assesses the current market landscape, and provides future market projections. It outlines ongoing research, regulatory developments, competitive positioning, and key market drivers and barriers to inform strategic decision-making.

---

Clinical Trials Update

Overview of Current Clinical Investigations

As of Q1 2023, over 40 active clinical trials globally focus on enoxaparin sodium, spanning applications for prophylaxis and treatment of thrombotic disorders, extended indications in oncology, and novel delivery systems. The trials are registered primarily across ClinicalTrials.gov, EudraCT, and the WHO ICTRP databases.

Trial Focus Area	Number of Trials	Major Investigators/Institutions	Geographies
Thromboprophylaxis in surgical and medical patients	20	Mayo Clinic, Johns Hopkins, UK NHS Trusts	US, Europe, Asia
Oncology-related thrombosis	8	MD Anderson, Memorial Sloan Kettering	US, Europe
Pregnancy-related thrombosis	5	Karolinska Institute, Singapore General Hospital	Europe, Asia
Novel delivery methods (e.g., subcutaneous injectables, implantables)	5	Novo Nordisk, BioMarin, Academic Labs	US, Europe

Key Clinical Trials Completed or Ongoing

Trial Name	Phase	Objective	Outcome/Status	Sponsor	Start Date	Completion Date (Projected)
ENOXAPS (NCT04079831)	Phase IV	Evaluate enoxaparin in DVT prevention post-Orthopedic surgery	Ongoing	Sanofi	Jan 2020	Dec 2023
ENOX-203 (NCT04327119)	Phase III	Efficacy in cancer-associated thrombosis	Recruiting	AstraZeneca	Feb 2021	Dec 2024
Novel Delivery Systems Study	Phase I	Biodegradable implant delivery of enoxaparin	Completed	Academic institution	Mar 2022	Dec 2023

Regulatory and Approval Updates

• US FDA: No recent indications approved beyond existing labels for prophylaxis and treatment of thrombotic events.
• EMA: Continues to monitor ongoing trials; no new indications authorized.
• China CFDA: Approved for use in thrombotic prophylaxis, with localized manufacturing increasing access.

Research Trends and Innovations

• Extended Indications: Increasing trials in oncology and pregnancy risks.
• Delivery Platforms: Development of sustained-release injectable formulations and implantable devices to enhance patient compliance.
• Biomarker Integration: Use of anti-factor Xa activity monitoring and pharmacogenomics to personalize dosing.

---

Market Analysis

Current Market Size and Segmentation

Segment	Market Size (2022 USD, bn)	Share	Major Players	Growth Rate (CAGR, 2022–2028)
Thrombosis prophylaxis	3.8	60%	Sanofi, GlaxoSmithKline	4.7%
Hospital treatment	2.0	31%	Pfizer, AstraZeneca	4.2%
Oncology-related uses	0.3	4%	Bayer, Eisai	5.1%
Other (e.g., pregnancy, implantable devices)	0.2	5%	Various	5.0%

Market Drivers

• Rising Incidence of Venous Thromboembolism (VTE): Global VTE prevalence is estimated at 1–2 per 1,000 population annually, with rising aging populations increasing the demand.
• Expanding Clinical Applications: Oncology, pregnancy, and outpatient prophylaxis broaden the scope.
• Enhanced Safety and Efficacy Profile: Favorable bleeding risk profile compared to unfractionated heparin.

Market Barriers

• Pricing and Reimbursement: High costs and payer restrictions challenge adoption.
• Generic Competition: Several biosimilars and generics entering markets, driving price pressure.
• Safety/Profile Concerns: Bleeding risks necessitate careful patient selection and management.

Key Market Players and Their Strategies

Company	Market Share (Estimated)	Key Strategies	Product Focus
Sanofi	35%	Portfolio expansion, biosimilar development	Lovenox, biosimilars
GlaxoSmithKline	20%	Partnering, pipeline innovation	Enoxaparin formulations
Pfizer	15%	Cost optimization, out-licensing	Enoxaparin biosimilars
Other	30%	Niche applications, regional expansion	Various

---

Market Projection and Future Trends

Projection Assumptions

• Growth Drivers: Aging populations, increasing VTE recognition, innovation in delivery systems.
• Obstacles: Regulatory delays, pricing pressures, biosimilar proliferation.
• Geographic Focus: US, Europe, emerging markets in Asia-Pacific.

Forecasted Market Size (2022–2028)

Year	Market Size (USD billion)	Compound Annual Growth Rate (CAGR)
2022	6.3	—
2023	6.6	4.8%
2024	7.0	6.0%
2025	7.4	6.3%
2026	8.0	7.0%
2027	8.7	7.8%
2028	9.4	8.0%

Key Future Dynamics

• Innovative Delivery Platforms: Sustained-release formulations aimed at outpatient settings.
• Regulatory Advancements: Faster approvals for new indications, especially in developing markets.
• Personalized Therapy: Integration of biomarker-driven dosing and risk stratification.
• Biosimilar and Generic Competition: Increased affordability, shifting market shares but compressing margins.

---

Comparison with Similar Anticoagulants

Drug	Class	Approved Indications	Route of Administration	Market Size (2022 USD bn)	Notable Competition	Price Point
Enoxaparin Sodium	LMWH	DVT, PE, MI	Subcutaneous	6.3	Dalteparin, Tinzaparin, Biosimilars	High
Fondaparinux	Pentasaccharide	Thrombosis prophylaxis/treatment	Subcutaneous	1.3	LMWHs, DOACs	Moderate
Rivaroxaban	Factor Xa inhibitor	VTE, stroke prevention	Oral	5.4	Apixaban, Edoxaban	Competitive

---

FAQs

1. What are the recent regulatory developments for enoxaparin sodium?

While no novel indications received recent approvals globally, regulators like the FDA and EMA continue to monitor ongoing clinical trials. Accelerated pathways and regional approvals facilitate broader access, particularly for biosimilars and extended indications.

2. How does enoxaparin sodium compete with direct oral anticoagulants (DOACs)?

Enoxaparin maintains a key role in inpatient, perioperative, and high-risk settings where parenteral administration and established safety profiles are crucial. DOACs offer oral convenience but lack wide approval for all indications, especially in pregnancy and certain cancer-related thrombosis.

3. What are the emerging indications for enoxaparin sodium?

Promising clinical trials target oncology-associated thrombosis, pregnancy-related prophylaxis, and novel delivery systems for outpatient management. However, these are pending regulatory validation.

4. How will biosimilars impact the enoxaparin market?

Biosimilars are projected to reduce pricing pressures, expand access in emerging markets, and increase competition, potentially leading to a reduction in average selling prices by up to 20-30%, depending on regional policies.

5. What are the main safety considerations associated with enoxaparin sodium?

Primary safety concern involves bleeding risks, which necessitate dose adjustments based on patient factors and anti-factor Xa monitoring. Rarely, heparin-induced thrombocytopenia (HIT) may occur.

---

Key Takeaways

• Clinical pipeline indicates ongoing expansion into oncology, pregnancy, and delivery innovations, potentially broadening therapeutic applications.
• Market size is expected to grow at approximately 6–8% CAGR through 2028, driven by demographic trends and clinical breakthroughs.
• Market dynamics favor innovation, biosimilar entry, and personalized therapies, with regional nuances influencing competitive strategies.
• Regulatory landscape remains cautious with approvals focused on established indications; however, emerging data may accelerate new indications.
• Strategic focus for stakeholders includes balancing pricing, fostering innovation, and navigating biosimilar competition to sustain market share.

---

References

[1] ClinicalTrials.gov. Enoxaparin-related trials. Accessed March 2023.
[2] MarketsandMarkets. Anticoagulant Market by Product, Application, and Region. 2022.
[3] World Health Organization. Venous Thromboembolism Fact Sheet. 2022.
[4] Sanofi Annual Report 2022.
[5] IMS Health Data Analytics. Global Hematology and Oncology Drugs Market, 2022.